Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Iontas
Iontas
Activities:
Ingredients
Pharmaceutical
X
LinkedIn
Trending Articles
Why Choose BioClean Nitrile RABS & Isolator Gloves
BioClean gloves: Superior durability and sustainable innovation for controlled environments
Helium: a precious and limited resource
As helium supplies face pressure, alternative solutions and regulatory changes drive industry adaptation
The benefits of disposable cleanroom coveralls & aseptic donning techniques
Minimising contamination risks in life sciences cleanrooms
Roche's multiple sclerosis drug fenebrutinib displays positive Phase II data
The drug was able to stop a majority of patients from relapsing, while also halting disability progression in the FENopta study
Enhancing processes for better, faster and more competitive manufacturing
Sustainable, reliable, high-quality processes address a variety of post-pandemic, geopolitical and sustainability challenges in the pharma industry
Upcoming event
Pharmaconex
8-10 September 2024 | Conference | Cairo, Egypt
See all
Related Content
Research & Development
IONTAS identifies SARS-CoV-2 variant neutralising antibodies
The company is now seeking development partners to progress the antibodies
Pharmaceutical
IONTAS celebrates 5 years of antibody discovery
The occasion marks a milestone for the company that provides discovery services and bespoke phage display libraries to the biotechnology and pharmaceutical industries
Pharmaceutical
IONTAS signs collaboration agreement with LG Chem
Under the agreement IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by LG Chem
Ingredients
Collaboration to identify antibodies for cancer targets
Iontas and IGEM Therapeutics will work together to develop novel immunoglobulin E antibodoes
Ingredients
Iontas to generate antibodies using mammalian display technology
Iontas to generate antibodies with favourable, binding and expression properties using its mammalian display antibody discovery platform
Subscribe now